Targeting c-Met and EMT, PI3K/Akt/mTOR/MEK signaling with Dihydropyrimidinone-Piperazine-based scaffold that triggers apoptosis, autophagy, and paraptosis in breast carcinomas
MCB-04 exerts robust anti-breast cancer activity by triggering multiple programmed cell death pathways include apoptosis, autophagy, and paraptosis primarily through ROS-mediated mitochondrial dysfunction and inhibition of c-Met-dependent oncogenic signaling. These findings position MCB-04 as a promising multi-targeted therapeutic candidate, warranting further in vivo validation and preclinical development for breast cancer treatment.
Authors
- Keshav Kumar Harish
- Kwang Seok Ahn
- Narasimha M. Beeraka (ORCID: https://orcid.org/0000-0001-6879-7835)
- Santosh L. Gaonkar (ORCID: https://orcid.org/0000-0003-2687-6927)
- Doddahosuru Mahadevappa Gurudatt (ORCID: https://orcid.org/0000-0003-3039-8593)
- Young Yun Jung (ORCID: https://orcid.org/0000-0002-9101-9641)
- M. Mahendra (ORCID: https://orcid.org/0000-0002-8543-1947)
- Basappa Basappa
- Bhoomika B R
- Kanchugarakoppal S. Rangappa
- Riyaz Ali M. Osmani
- Shreeja Basappa
- Monisha Yadav H S
- Vladimir N. Nikolenko
Institutions
- Manipal Academy of Higher Education (IN)
- Sechenov University (RU)
- University of Mysore (IN)
- Kyung Hee University (KR)
- Birla Institute of Technology and Science - Hyderabad Campus (IN)
- King Khalid University (SA)
- Saveetha University (IN)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1016/j.biopha.2026.119059
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00